{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:31:51Z","timestamp":1762165911693,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00580-1","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:26:39Z","timestamp":1762165599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-5918","authenticated-orcid":false,"given":"Haruki","family":"Sawada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-1993","authenticated-orcid":false,"given":"Kurisu","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0293-8911","authenticated-orcid":false,"given":"Gautam A.","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-2088","authenticated-orcid":false,"given":"Daiki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0357-0127","authenticated-orcid":false,"given":"Masato","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-5330","authenticated-orcid":false,"given":"Diego","family":"Benavent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3503-9047","authenticated-orcid":false,"given":"Chamaida","family":"Plasencia-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-5837","authenticated-orcid":false,"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-1986","authenticated-orcid":false,"given":"Anna","family":"Molto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-2954","authenticated-orcid":false,"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"9","key":"580_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"580_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55\u201378.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"580_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewe RBM, Van den Bosch FE, Boteva B, Bremander A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"580_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, et al. EULAR recommendations for the management of psoriatic arthritis with Pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"580_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.semarthrit.2021.04.018","volume":"51","author":"D Benavent","year":"2021","unstructured":"Benavent D, Plasencia C, Poddubnyy D, Kishimoto M, Proft F, Sawada H, Lopez-Medina C, Dougados M, Navarro-Compan V. Unveiling axial involvement in psoriatic arthritis: an ancillary analysis of the ASAS-perSpA study. Semin Arthritis Rheum. 2021;51(4):766\u201374.","journal-title":"Semin Arthritis Rheum"},{"key":"580_CR6","doi-asserted-by":"publisher","first-page":"1759720X2110579","DOI":"10.1177\/1759720X211057975","volume":"13","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy D, Baraliakos X, Van den Bosch F, Braun J, Coates LC, Chandran V, Diekhoff T, van Gaalen FA, Gensler LS, Goel N, et al. Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the assessment of spondyloarthritis international society (ASAS) and the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA). Ther Adv Musculoskelet Dis. 2021;13:1759720X211057975.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"580_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0923-1811(02)00142-1","volume":"31","author":"A Kawada","year":"2003","unstructured":"Kawada A, Tezuka T, Nakamizo Y, Kimura H, Nakagawa H, Ohkido M, Ozawa A, Ohkawara A, Kobayashi H, Harada S, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31(1):59\u201364.","journal-title":"J Dermatol Sci"},{"issue":"Suppl 2","key":"580_CR8","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18\u201323. discussion ii24-15.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"580_CR9","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3899\/jrheum.141598","volume":"42","author":"Y Ohara","year":"2015","unstructured":"Ohara Y, Kishimoto M, Takizawa N, Yoshida K, Okada M, Eto H, Deshpande GA, Ritchlin CT, Tanaka A, Higashiyama M, et al. Prevalence and clinical characteristics of psoriatic arthritis in Japan. J Rheumatol. 2015;42(8):1439\u201342.","journal-title":"J Rheumatol"},{"issue":"4","key":"580_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"580_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/tan.12536","volume":"85","author":"N Ikeda","year":"2015","unstructured":"Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, Kusunoki Y, Fujii N, Suegami S, Miyazaki Y, et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens. 2015;85(4):252\u20139.","journal-title":"Tissue Antigens"},{"issue":"1","key":"580_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12886-020-01472-3","volume":"20","author":"JI Kim","year":"2020","unstructured":"Kim JI, Park CY. A case of severe flare reaction observed in HLA B27 associated acute anterior uveitis. BMC Ophthalmol. 2020;20(1):201.","journal-title":"BMC Ophthalmol"},{"key":"580_CR13","doi-asserted-by":"crossref","unstructured":"Lopez-Medina C, Chevret S, Molto A, Sieper J, Duruoz T, Kiltz U, Elzorkany B, Hajjaj-Hassouni N, Burgos-Vargas R, Maldonado-Cocco J et al. Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open 2021, 7(3).","DOI":"10.1136\/rmdopen-2021-001728"},{"key":"580_CR14","doi-asserted-by":"crossref","unstructured":"Lopez-Medina C, Molto A, Sieper J, Duruoz T, Kiltz U, Elzorkany B, Hajjaj-Hassouni N, Burgos-Vargas R, Maldonado-Cocco J, Ziade N et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open 2021, 7(1).","DOI":"10.1136\/rmdopen-2020-001450"},{"issue":"4","key":"580_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the new York criteria. Arthritis Rheum. 1984;27(4):361\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"580_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"580_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"580_CR18","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"580_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pain.2010.03.034","volume":"150","author":"S Perrot","year":"2010","unstructured":"Perrot S, Bouhassira D, Fermanian J, Cedr. Development and validation of the fibromyalgia rapid screening tool (FiRST). Pain. 2010;150(2):250\u20136.","journal-title":"Pain"},{"issue":"12","key":"580_CR20","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"1","key":"580_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Assessment of spondyloarthritis international S: development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"580_CR22","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, Kennedy LG, O\u2019Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21(12):2281\u20135.","journal-title":"J Rheumatol"},{"issue":"9","key":"580_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, Wei JC, Chiowchanwisawakit P, Dougados M, Duruoz MT, et al. Measurement properties of the ASAS health index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77(9):1311\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"580_CR24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/rheumatology\/kez629","volume":"59","author":"PS Helliwell","year":"2020","unstructured":"Helliwell PS. Axial disease in psoriatic arthritis. Rheumatology (Oxford). 2020;59(6):1193\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"580_CR25","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.171094","volume":"45","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona psoriatic Arthritis\/Spondyloarthritis registry. J Rheumatol. 2018;45(10):1389\u201396.","journal-title":"J Rheumatol"},{"issue":"6","key":"580_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jaad.2009.09.053","volume":"63","author":"S Bremmer","year":"2010","unstructured":"Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr., Blauvelt A, National Psoriasis F. Obesity and psoriasis: from the medical board of the National psoriasis foundation. J Am Acad Dermatol. 2010;63(6):1058\u201369.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"580_CR27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1001\/archdermatol.2010.204","volume":"146","author":"AA Qureshi","year":"2010","unstructured":"Qureshi AA, Dominguez PL, Choi HK, Han J, Curhan G. Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol. 2010;146(12):1364\u20139.","journal-title":"Arch Dermatol"},{"issue":"5","key":"580_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/aje\/kwr325","volume":"175","author":"W Li","year":"2012","unstructured":"Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the united states: a combined analysis. Am J Epidemiol. 2012;175(5):402\u201313.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"580_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/BOR.0000000000000136","volume":"27","author":"L Eder","year":"2015","unstructured":"Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol. 2015;27(1):91\u20138.","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"580_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","volume":"76","author":"DR Jadon","year":"2017","unstructured":"Jadon DR, Sengupta R, Nightingale A, Lindsay M, Korendowych E, Robinson G, Jobling A, Shaddick G, Bi J, Winchester R, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017;76(4):701\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"580_CR31","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00776-015-0755-z","volume":"20","author":"A Otsuka","year":"2015","unstructured":"Otsuka A, Morita M, Yamada H. Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab. J Orthop Sci. 2015;20(6):1070\u20137.","journal-title":"J Orthop Sci"},{"issue":"1","key":"580_CR32","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","volume":"19","author":"R Micheroli","year":"2017","unstructured":"Micheroli R, Hebeisen M, Wildi LM, Exer P, Tamborrini G, Bernhard J, Moller B, Zufferey P, Nissen MJ, Scherer A, et al. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2017;19(1):164.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"580_CR33","doi-asserted-by":"publisher","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS ONE. 2018;13(5):e0195123.","journal-title":"PLoS ONE"},{"issue":"5","key":"580_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, Schulz B, Rissler M, Nagar K, Perella C, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"580_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71(2):258\u201370.","journal-title":"Arthritis Rheumatol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00580-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00580-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:26:41Z","timestamp":1762165601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00580-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00580-1","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines for Good Clinical Practice and was approved by the ethical committees of the Juntendo University Hospital (Approval number: 18\u2013211). Written informed consent was obtained from all subjects before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"MK received consulting fees and\/or honoraria from AbbVie, Amgen-Astellas BioPharma, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB Pharma. KT has received speaker fees from AbbVie, Amgen, Mitsubishi-Tanabe, Janssen, Eisai, Eli Lilly Japan, Novartis and Kyowa Kirin. MO is a consultant for AbbVie, Eli Lilly, and is on the speaker\u2019s bureau of AbbVie Japan, Eli Lilly and Company, and Ono Pharmaceutical. VN-C: has received research grants\/honoraria from AbbVie, Janssen, Lilly, Novartis, Pfizer, and UCB. CL-M received consulting fees and\/or honoraria form Lilly, UCB, AbbVie, Janssen and Novartis. NT: has received speaker fees and\/or consulting fees from AbbVie, Astellas, Bristol-Myers, Squibb, Eisai, Eli Lilly, Janssen, Kyowa Kirin, Mitsubishi-Tanabe and Novartis. All other authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}